indication

Obesity

Competitive landscape projected to nicotine transdermal patch/lozenge’s launch window

as of 2026-07-01
Competitive set
4
4 approved · 0 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
40 events
2020
2024
2028
2032
2036
2040
today
nicotine transdermal patch/lozenge launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Aripiprazole
US-approved 2002 · ABILIFY
Phase 43 trials
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugCompleted
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
—2 trials
OwnerEli Lilly and Company
Protection2041
drugCompleted
Risperidone
US-approved 1993 · RISPERDAL
—1 trial
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugCompleted
Haloperidol
US-approved 1986 · Haldol Decanoate
—1 trial
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection—

Market size

prevalence as a range, not a number